<DOC>
	<DOCNO>NCT01830127</DOCNO>
	<brief_summary>To assess pharmacokenetic characteristic 600 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin small number GT1b HCV infect patient mild hepatic impairment ( CPA ) ( Arm 1 ) versus 400 mg BID BI 207127 / 120 mg QD faldaprevir /ribavirin small number GT1b HCV infect patient moderate hepatic impairment ( CPB ) ( Arm 2 ) .</brief_summary>
	<brief_title>BI 207127 / Faldaprevir Combination Therapy Hepatic Impairment ( Child-Pugh B ) Patients With Genotype 1b Chronic Hepatitis C Infection : HCVerso3</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : 1 . Treatment na√Øve treatment experience patient ( prior relapse , interferon intolerant , [ allow Cohort A ] prior partial response ) . 2 . Chronic HCV infection genotype 1 ( GT1 ) , subGT1b virus . 3 . Liver cirrhosis define Metavir Grade=4 Ishak Grade =5 liver biopsy liver stiffness =13 kPa fibroscan . Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) mixed subGT1a/1b undefined diagnosed genotypic test screen 2 . Liver disease due cause chronic HCV infection may include limited hemochromatosis , Wilson 's disease , autoimmune liver disease . 3 . HIV infection 4 . Patients previously treat investigational approve DAA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>